- Poseida Therapeutics (PSTX -0.1%) and TScan Therapeutics have entered into a research collaboration and license agreement to explore development of TCR-T cell therapies for the treatment of COVID-19.
- Poseida's allogeneic T cell platform will be used in combination with TScan's immunodominant epitopes and TCR sequences for the development and commercialization of allogeneic TCR-T cell therapies.
- Detailed financial terms of the collaboration were not disclosed.
- https://seekingalpha.com/news/3624316-poseida-therapeutics-inks-license-pact-tscan-therapeutics-for-covidminus-19-therapies
Wednesday, October 21, 2020
Poseida Therapeutics in license pact with TScan Therapeutics for COVID-19 therapies
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.